
Please try another search
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Arvinas (ARVN) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Arvinas is a member of the Medical sector. This group includes 898 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ARVN is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ARVN's full-year earnings has moved 1.36% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that ARVN has returned about 0.17% since the start of the calendar year. At the same time, Medical stocks have lost an average of 19.92%. This means that Arvinas is outperforming the sector as a whole this year.
To break things down more, ARVN belongs to the Medical - Biomedical and Genetics industry, a group that includes 385 individual companies and currently sits at #72 in the Zacks Industry Rank. Stocks in this group have lost about 12.53% so far this year, so ARVN is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track ARVN. The stock will be looking to continue its solid performance.
Since the Robotaxi event on October 11th, Tesla (NASDAQ:TSLA) stock is up 38%, currently priced at $291.60 per share This is a return to the early November 2024 price level. But...
The Q4 2024 earnings season tapers off from here, with S&P 500® EPS growth surpassing 17%, the highest in 3 years Large cap outlier earnings dates this week include:...
Shares of Alibaba (NYSE:BABA) are on a tear to start off 2025. The consumer discretionary and tech stock is up by 52% this year as of the Feb. 25 close. The company’s cloud...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.